Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Christopher Stuart

Physician Assistant, Surgical Brighton, MI Physician Assistant

NPI 1356500912 CMS profile 11087689

2305 Genoa Business Park Dr, Suite 170, Brighton, MI 48114

Open in the dashboard

General payments

$2,547

32 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Stuart of Brighton, MI is reported in the CMS Open Payments database as having received $2,547 across 32 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,337 13
2024 General $43 2
2023 General $1,046 16
2022 General $120 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Stuart
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Christopher Stuart were reported at $1,337. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Christopher Stuart Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $111 $36–$285 $132
2022 $120 $126 $44–$350 $149
2023 $1,046 $137 $47–$355 $160
2024 $43 $146 $49–$384 $164
2025 $1,337 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Pinnacle, Inc $1,261 12 payments
  2. Arthrex, Inc. $1,243 18 payments
  3. Avanos Medical $26 1 payment
  4. Medtronic, Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Travel and Lodging $1,681 6 payments
  2. Food and Beverage $865 26 payments
Products named General payments · program years 2022–2025
  1. ON-Q* PUMP AND ACCESSORIES $26 1 payment
  2. AQUAMANTYS(TM) $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

256

Median for Physician Assistant: 241

Drug cost

$1,462

Median for Physician Assistant: $4,110

Branded share of claims

62.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 91 $530
Ondansetron Odt Ondansetron Brand 15 $259
Celecoxib Generic 38 $227
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 41 $214
Oxycodone Hcl Generic 17 $81
Acetaminophen-Codeine Acetaminophen With Codeine Brand 12 $77
Meloxicam Generic 25 $54
Tramadol Hcl Generic 17 $20

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$51,339

Of which drugs: $9,295

Medicare patients

274

Average age 72

Services billed

1,391

152 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 63%
Ischemic heart disease 28%
Depression 19%
Diabetes 16%
Chronic kidney disease 15%
Atrial fibrillation 14%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 41 156 $8,829
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 85 392 $308
Injection, methylprednisolone acetate, 40 mg J1030 Office 30 36 $158

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record